Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | The omega score: an emerging biomarker for risk determination

Hisham Mehanna • 29 Nov 2018
ESMO 2018
Head and Neck Cancer Cetuximab Monalizumab

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), of the University of Birmingham, Birmingham, UK, reflects on an interesting biomarker study suggesting a role for the omega score as a clinical classifier of risk of death due to the tumor vs. other causes in cancer patients. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Prof. Mehanna, further explores the potential clinical application of omega in patient selection for treatment intensification, before discussing the results from a current clinical trial investigating a combination of monalizumab and cetuximab in recurring metastatic cancer patients.

More from Hisham Mehanna

Improving patient selection for surgical candidates with head and neck cancer
2:27
Improving patient selection for surgical candidates with head and neck cancer
Hisham Mehanna • 28 Sep 2019
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
3:58
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
Hisham Mehanna • 30 Sep 2019
Changes in the staging system for HPV+ cancer patients
2:31
Changes in the staging system for HPV+ cancer patients
Hisham Mehanna • 29 Nov 2018
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
1:23
Evaluating options for HPV+ oropharyngeal cancer: cisplatin-RT vs. cetuximab-RT
Hisham Mehanna • 29 Nov 2018

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals